Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AP-160 |
| Synonyms | |
| Therapy Description |
AP-160 is a complex composed of nab-paclitaxel and the PD-L1 (CD274)-targeting antibody danburstotug, which potentially induces death of PD-L1 (CD274)-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AP-160 | AP160|AP 160|nab-paclitaxel/STI-3031 complex|nab-paclitaxel/danburstotug complex | PD-L1/PD-1 antibody 132 | AP-160 is a complex composed of nab-paclitaxel and the PD-L1 (CD274)-targeting antibody danburstotug, which potentially induces death of PD-L1 (CD274)-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05653661 | Phase I | AP-160 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | Withdrawn | USA | 0 |